STAT April 29, 2024
Meghana Keshavan

Morning! Today, we learn there are some serious safety concerns around an experimental blood cancer drug from MorphoSys that has been the centerpiece of Novartis’ plan to acquire the company for $3 billion. Also, Doctors Without Borders is challenging the pharmaceutical industry to be more transparent about its dollars and cents, and we see more movement in the BIOSECURE Act.

The need-to-know this morning

  • Ono Pharmaceutical of Japan is buying Boston-based Deciphera Pharmaceuticals, a maker of cancer drugs, for $2.4 billion.
  • Daiichi Sankyo and AstraZeneca said their targeted cancer drug Enhertu showed a statistically significant and clinically meaningful slowing of tumor progression in a randomized, Phase 3 study involving patients with hormone-positive, HER2-low metastatic breast cancer.
  • The FDA approved...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Congress / White House, Govt Agencies, Pharma / Biotech
Related Articles:
Wegovy could bankrupt US health system, Sanders says in new report
Congress can help curb high health care costs—it starts with primary care
AI Regulation: Senators Unveil AI Plan, Open AI CEO Wants International Agency
AI needs the non-quants, too
Lawmakers push for primary care payment reform

Share This Article